CAR T-cell therapyB7-H3-directed CAR T-cell therapyResiquimodPOx-RmedulloblastomaG3MB
…G3MB) is the most aggressive medulloblastoma subgroup. Although CAR T-cell therapy is promising, it has shown limited efficacy in G3MB due to poor…
7,227articles mentioning treatments
16,644treatment mentions
4,719distinct treatments extracted
0%of mentions human-reviewed
All extracted treatments
Showing 3,361–3,420 of 4,719, ordered by supporting articles. Choose a treatment to see its evidence.
endoscopic coblation1endoscopic decompression1endoscopic dilatation1endoscopic eradication therapy1endoscopic full thickness resection1endoscopic haemostatic clips1endoscopic intermuscular dissection1endoscopic laryngopharyngeal surgery1endoscopic pancreatic sphincterotomy1endoscopic stent placement1endoscopic surveillance1endothelin-1 treatment1endotherapy1endothermal ablation1endovascular aneurysm therapy1endovascular aspiration1endovascular balloon angioplasty1endovascular device closure1endovascular fistula embolization1endovascular flow diversion1endovascular intervention therapy1endovascular rescue treatment1endovascular retrieval1endovascular sinus stenting1endovascular treatments1enfortumab-vedotin therapy1engagement strategies1engineered therapies1enteral and transdermal medications1enteral/parenteral nutrition1enterotomy1enucleation1environmental decontamination1epi-off CXL1epidural blood patches1epidural blood patching1epidural labour analgesia1epidurolysis1epithelial debridement1erythrocytapheresis1esophageal dilatation1esophagectomy1ethanol embolization1ethanol endovascular therapy1ethanol injection1eudaimonia1evidence-based treatment1excision of the mass1exclusive breastfeeding1exercise therapies1exercise-based prehabilitation1exercise-based rehabilitation1exogenous surfactant therapy1exon skipping1expectant management1extended window TNK thrombolysis1external carotid artery embolizations1external ventricular drain placement1extracorporeal circulation1extracorporeal life support1
Articles mentioning treatments
7,227 articles · page 130 of 603RPT177Lu-PSMA-617metastatic castration-resistant prostate cancermetastatic castration-resistant prostate cancer (mCRPC)mCRPCcyclophosphamideCyNCT03873805
…stry were monitored to evaluate the efficacy and safety.Results RPT and Cy treatment alter the endogenous immune landscape in the m…
IL-12 GEMy therapyCy/FluOsteosarcomacyclophosphamiderhabdomyosarcomafludarabineNational Institutes of Health
…stasis, making it an important disease for continued studies of IL-12 GEMy therapy.Methods F42010 murine syngeneic osteosarcoma cells were orthoto…
stem cell treatmentsadoptive cell therapiesadoptive cell therapycancerantibody therapies
… drugs such as antibody therapies, adoptive cell therapies, and stem cell treatments. Understanding complex biological systems requires extensive te…
tdRT_SLNAdoptive cell therapyUniversity of California San DiegoHead and neck squamous cell carcinoma (HNSCC)Gleiberman Head and Neck Cancer CentertdRTHNSCC
…RT_SLN mice remained tumor-free for the entirety of experiment. tdRT_SLN also showed highest survival ( figure 1B-C). Data was analyzed …
E7 TCR-T cell therapyT cell receptor (TCR)-T cell therapymelanomasynovial cell sarcomasynovial sarcomahuman papillomavirus (HPV)-associated cancersNIH IRB
…vardict and strelka.Results Patient 4 had primary resistance to E7 TCR-T cell therapy due to a nonsense mutation at amino acid position 51 in the α1 …
neoadjuvant immunochemotherapyNSCLC
…e II, IIIA, and IIIB (N2) NSCLC (AJCC 8th edition) treated with neoadjuvant immunochemotherapy, with or without adjuvant therapy. Baseline characteristics, tr…
chemotherapystereotactic body radiotherapyNivolumabBiliary tract canceripilimumabPembrolizumabgemcitabineGranzyme Bcisplatin
… with chemotherapy as first-line therapy for BTC is superior to chemotherapy alone, most patients still do not benefit from treatment.2 This…
platinum chemotherapyplatinum-doublet chemotherapyanti-PD-(L)1 therapymNSCLCdocetaxelpembrolizumabvibo/pembrovibostolimab
…axel in mNSCLC previously treated with anti-PD-(L)1 therapy and platinum chemotherapy. No significant difference in PFS was observed between vibo/pem…
lymphodepleting chemotherapyLDCLEU011solid tumorssolid tumoursLEU01101ClinicalTrials.govNorth East - York Research Ethics Committee
… linear CAR. The trial hypothesis is that LEU011, combined with lymphodepleting chemotherapy (LDC), will be safe and tolerable, and will elicit efficacy in …
RPT[67Cu]Cu-LLP2Aneuroblastomasolid tumors[ 67Cu]Cu-LLP2A67Cu]Cu-LLP2Ahematological malignanciesSK-N-ASNIH institutional IACUCNB
…he tumors in both SK-N-AS and IMR-5.Conclusions [ 67Cu]Cu-LLP2A RPT improves CAR T-cell efficacy by direct tumoricidal effects and …